No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database

2019 ◽  
Vol 37 (3) ◽  
pp. 249-257 ◽  
Author(s):  
Catherine Tsai ◽  
Alexandra Mueller ◽  
Johannes Maubach ◽  
Rene Warschkow ◽  
Daniel P. Nussbaum ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Chemoradiation Therapy ◽  
Gastric Cardia ◽  
Survival Outcomes ◽  
National Cancer Database ◽  
Cardia Cancer ◽  
Adjuvant Chemoradiation ◽  
Gastric Cardia Cancer ◽  
Neo Adjuvant Chemotherapy

Introduction: Both neo-adjuvant chemoradiation therapy (NACRT) and neo-adjuvant chemotherapy (NAC), in addition to surgical resection of gastric cardia cancer, improves survival outcomes. We assessed whether NACRT or NAC had superior overall survival (OS) and relative survival (RS) outcomes using the National Cancer Database (NCDB). Methods: The NCDB from 2006 to 2014 was reviewed to identify non-metastatic adult gastric cardia cancer patients who underwent surgical resection and received NACRT or NAC. Advanced statistical models were applied to assess survival outcomes. Results: Of the 5,371 patients included, 4,520 (84.2%) were male, the mean age was 61.2 years (SD 10.0), 4,229 (78.7%) underwent NACRT, and 1,142 (21.3%) underwent NAC. NACRT patients more often had an R0 resection compared to NAC (91.4 vs. 86.6%, p < 0.001, respectively). Univariate 5-year OS rates were 40.0% (95% CI 38.2–41.8) for NACRT and 40.1% (37.0–43.6) for NAC (p = 0.302). No differences in OS for NAC vs. NACRT were found after multivariable analysis (hazard ratio [HR] 0.95, 95% CI 0.86–1.05, p = 0.290). There were no survival differences after stepwise, propensity score, RS analyses, nor after near-far-matching (HR 0.94, 95% CI 0.82–1.07, p = 0.332). Conclusions: NAC or NACRT yield the same survival outcome for patients with resectable gastric cardia cancer. These data support the need for randomized controlled trials comparing the 2 regimens head-to-head.

scholarly journals Patrilineal Background of Esophageal Cancer and Gastric Cardia Cancer Patients in a Chaoshan High-Risk Area in China

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e81670 ◽  
Author(s):  
Shuhui Liu ◽  
Bo Huang ◽  
Haihua Huang ◽  
Xiaoyun Li ◽  
Guangcan Chen ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Gastric Cardia ◽  
Cardia Cancer ◽  
Risk Area ◽  
High Risk Area ◽  
Gastric Cardia Cancer

Utility of EUS to identify the effective responders from rectal cancer patients who receive neo-adjuvant chemotherapy

Endoscopy ◽  
2011 ◽  
Vol 43 (S 03) ◽  
Author(s):  
Zhang Xiaoyin ◽  
Guo Xuegang ◽  
Wang Xin ◽  
Du Jianjun ◽  
Zhao Qingchuan ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Neo Adjuvant Chemotherapy

scholarly journals Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients

2021 ◽  
Author(s):  
Shozo Ohsumi ◽  
Sachiko Kiyoto ◽  
Mina Takahashi ◽  
Seiki Takashima ◽  
Kenjiro Aogi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Prospective Study ◽  
Cancer Patients ◽  
Scalp Cooling ◽  
Breast Cancer Patients ◽  
Chemotherapy Infusion ◽  
Group A ◽  
Neo Adjuvant Chemotherapy ◽  
Group B

Abstract Purpose Scalp cooling during chemotherapy infusion to mitigate alopecia for breast cancer patients is becoming widespread; however, studies regarding hair recovery after chemotherapy with scalp cooling are limited. We conducted a prospective study of hair recovery after chemotherapy with scalp cooling. Patients and methods One hundred and seventeen Japanese female breast cancer patients who completed planned (neo)adjuvant chemotherapy using the Paxman Scalp Cooling System for alopecia prevention were evaluated for alopecia prevention in our prospective study. We evaluated their hair recovery 1, 4, 7, 10, and 13 months after chemotherapy. Primary outcomes were grades of alopecia judged by two investigators (objective grades) and patients’ answers to the questionnaire regarding the use of a wig or hat (subjective grades). Results Of 117 patients, 75 completed scalp cooling during the planned chemotherapy cycles (Group A), but 42 discontinued it mostly after the first cycle (Group B). Objective and subjective grades were significantly better in Group A than in Group B throughout 1 year, and at 4 and 7 months after chemotherapy. When we restricted patients to those with objective Grade 3 (hair loss of > 50%) at 1 month, Group A exhibited slightly faster hair recovery based on the objective grades than Group B. There was less persistent alopecia in Group A than in Group B. Conclusions Scalp cooling during chemotherapy infusion for Japanese breast cancer patients increased the rate of hair recovery and had preventive effects against persistent alopecia.

scholarly journals Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands

2012 ◽  
Vol 48 (11) ◽  
pp. 1624-1632 ◽  
Author(s):  
Johan L. Dikken ◽  
Valery E. Lemmens ◽  
Michel W.J.M. Wouters ◽  
Bas P. Wijnhoven ◽  
Peter D. Siersema ◽  
...  
Keyword(s):  
The Netherlands ◽  
Oesophageal Cancer ◽  
Gastric Cardia ◽  
Cardia Cancer ◽  
Gastric Cardia Cancer

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

2007 ◽  
Vol 25 (25) ◽  
pp. 3859-3865 ◽  
Author(s):  
Thomas M. Suter ◽  
Marion Procter ◽  
Dirk J. van Veldhuisen ◽  
Michael Muscholl ◽  
Jonas Bergh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Adverse Effects ◽  
Cancer Patients ◽  
Cardiac Dysfunction ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Breast Cancer Patients ◽  
Ventricular Ejection Fraction ◽  
Neo Adjuvant Chemotherapy

Purpose The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy. Patients and Methods The Herceptin Adjuvant (HERA) trial is a three-group, multicenter, open-label randomized trial that compared 1 or 2 years of trastuzumab given once every 3 weeks with observation in patients with HER-2–positive breast cancer. Only patients who after completion of (neo)adjuvant chemotherapy with or without radiotherapy had normal left ventricular ejection fraction (LVEF ≥ 55%) were eligible. A repeat LVEF assessment was performed in case of cardiac dysfunction. Results Data were available for 1,693 patients randomly assigned to 1 year trastuzumab and 1,693 patients randomly assigned to observation. The incidence of trastuzumab discontinuation due to cardiac disorders was low (4.3%). The incidence of cardiac end points was higher in the trastuzumab group compared with observation (severe congestive heart failure [CHF], 0.60% v 0.00%; symptomatic CHF, 2.15% v 0.12%; confirmed significant LVEF drops, 3.04% v 0.53%). Most patients with cardiac dysfunction recovered in fewer than 6 months. Patients with trastuzumab-associated cardiac dysfunction were treated with higher cumulative doses of doxorubicin (287 mg/m2 v 257 mg/m2) or epirubicin (480 mg/m2 v 422 mg/m2) and had a lower screening LVEF and a higher body mass index. Conclusion Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.

A Fully-Covered Stent (Alimaxx-E™) for the Palliation of Dysphagia from Esophageal and Gastric Cardia Cancer: A Prospective Study

2008 ◽  
Vol 67 (5) ◽  
pp. AB250 ◽  
Author(s):  
Madeleen Uitdehaag ◽  
Jeanin Van Hooft ◽  
E.M. Verschuur ◽  
Alessandro Repici ◽  
E.W. Steyerberg ◽  
...  
Keyword(s):  
Prospective Study ◽  
Covered Stent ◽  
Gastric Cardia ◽  
Cardia Cancer ◽  
Gastric Cardia Cancer ◽  
A Prospective Study
Sign in / Sign up

Export Citation Format

Share Document